Technical Analysis for TLX - Telix Pharmaceuticals Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Shooting Star Candlestick | Bearish | -0.43% | |
| Calm After Storm | Range Contraction | -0.43% | |
| Doji - Bearish? | Reversal | -0.43% | |
| Gapped Down | Weakness | -0.43% | |
| New 52 Week Closing High | Bullish | -2.40% | |
| Spinning Top | Other | -2.40% | |
| Calm After Storm | Range Contraction | -2.40% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 19 hours ago |
| Down 5% | about 19 hours ago |
| Down 3% | about 19 hours ago |
| Shooting Star Candlestick Entry | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Prostate Cancer Glioblastoma Cancer Care Brain Cancer Pharmaceutical Industry In India Radiopharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Prostate Cancer Glioblastoma Cancer Care Brain Cancer Pharmaceutical Industry In India Radiopharmaceutical Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.99 |
| 52 Week Low | 14.4399 |
| Average Volume | 22,319 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 16.14 |
| Average True Range | 0.81 |
| RSI (14) | 64.29 |
| ADX | 0.0 |
| +DI | 30.42 |
| -DI | 13.30 |
| Chandelier Exit (Long, 3 ATRs) | 17.55 |
| Chandelier Exit (Short, 3 ATRs) | 16.88 |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.35 |
| MACD Signal Line | 0.21 |
| MACD Histogram | 0.1392 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.77 | ||||
| Resistance 3 (R3) | 17.67 | 17.08 | 17.53 | ||
| Resistance 2 (R2) | 17.08 | 16.71 | 17.13 | 17.44 | |
| Resistance 1 (R1) | 16.69 | 16.47 | 16.89 | 16.79 | 17.36 |
| Pivot Point | 16.10 | 16.10 | 16.20 | 16.15 | 16.10 |
| Support 1 (S1) | 15.71 | 15.73 | 15.91 | 15.81 | 15.24 |
| Support 2 (S2) | 15.12 | 15.49 | 15.17 | 15.16 | |
| Support 3 (S3) | 14.73 | 15.12 | 15.08 | ||
| Support 4 (S4) | 14.83 |
